Celiac Disease (CED-LA-3001)

Celiac Disease, according to the Canadian Celiac Association, is a condition in which the absorptive surface of the small intestine is damaged by a substance called gluten. Gluten is a group of proteins present in wheat, rye and barley and their cross bred grains. The damage to the intestine can lead to a variety of symptoms and result in an inability of the body to absorb nutrients such as protein, fat, carbohydrates, vitamins and minerals, which are necessary for good health.

CED-LA-3001 is clinical trial to assess the efficacy and safety of larazotide acetate versus placebo for the treatment of persistent abdominal symptoms in adult celiac disease patients.

Register Today!

Trial Information

Start DateTBD
End DateJune 2020
Trial Duration2 Years
Number of VisitsTBD
Lead CRCJessica Richer

For additional information on this trial contact: